Study Shows GraMedica’s HyProCure® Ankle Bone Stabilization Stent is Still the Superior Option

Macomb, Mich.— A recent study published in the Journal of Foot and Ankle Surgery1 (JFAS)—a prestigious, peer-reviewed medical journal—showed the HyProCure® sinus tarsi stent to have a higher success rate over other “arthroereisis” devices.
 
 
The HyProCure® Stent
The HyProCure® Stent
 
Spread the Word
Listed Under

Tags:
Hyprocure
Feet
Podiatry

Industry:
Health

Location:
Michigan - US

Feb. 18, 2016 - PRLog -- Macomb, Mich.— A recent study published in the Journal of Foot and Ankle Surgery1 (JFAS)—a prestigious, peer-reviewed medical journal—showed the HyProCure® sinus tarsi stent to have a higher success rate over other “arthroereisis” devices.

Arthroereisis, or Type I, devices block or limit joint range-of-motion and have published removal rates of up to 100%2. While the JFAS study reports 22 percent of participants had the Type I device removed, it admits that a “lack of some follow up data was a limitation of the study” and “the incidence of implant removal could have been greater.” Researchers found the leading complicating factor was the size of the arthroereisis device implanted.

HyProCure, by GraMedica®, has been proven to have the highest success rate of all sinus tarsi devices, with a removal rate of approximately 6 percent3. Classified as a Type II device, HyProCure is placed into a naturally occurring space located between the ankle (talus) and heel bone (calcaneus), called the sinus tarsi. This is a stark contrast to the Type I arthroereisis devices that are only placed in the outer portion of the chamber, and function against, rather than with, the natural ankle bone motion. When indicated, HyProCure is routinely used in both pediatric and adult patients.

To learn more about HyProCure and misaligned feet, please visit: www.AlignMyFeet.com

About GraMedica
GraMedica is a global foot care solutions company passionate about creating innovative foot and ankle products that improve patient options and outcomes. Together with our sister organization, the Graham International Implant Institute (GIII), we educate foot and ankle surgeons in over 60 countries. We are committed to helping create ongoing improvement in the quality of healthcare for both patients and physicians through premier product lines including HyProCure, osteo-WEDGE™ and Soleus Foot Care Solution. To learn more, please visit our website at www.GraMedica.com. For more information on HyProCure®, please visit HyProCure.com.

1.       Journal of Foot and Ankle Surgery: Subtalar Arthroereisis Implant Removal in Adults: A Prospective Study of 100 Patients

2.       Journal of Foot and Ankle Surgery: Extraosseous Talotarsal Stabilization Devices: A New Classification System

3.       Journal of Foot and Ankle Surgery: Extraosseous Talotarsal Stabilization Using HyProCure®in Adults: A 5-year Retrospective Follow-up

Contact
Brooke Naeyaert, Media relations, GraMedic
***@gramedica.com
End
Source:GraMedica®
Email:***@gramedica.com Email Verified
Tags:Hyprocure, Feet, Podiatry
Industry:Health
Location:Michigan - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Graham International Implant Institute PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share